Tonapofylline - CAS 340021-17-2
Catalog number: 340021-17-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H32N4O4
Molecular Weight:
416.24
COA:
Inquire
Targets:
Others
Description:
Tonapofylline, a selective adenosine-1 receptor antagonist, has natriuretic effects and is able to maintain renal function, which can be beneficial to patients with congestive heart failure.
Purity:
≥98%
Appearance:
Solid powder
Synonyms:
BG9928; BG-9928; BG 9928; Tonapofylline.3-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)bicyclo[2.2.2]octan-1-yl)propanoic acid;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Adenosine A1 receptor antagonists; Adenosine A2B receptor antagonists
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
InChIKey:
ZWTVVWUOTJRXKM-UHFFFAOYSA-N
InChI:
1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)
Canonical SMILES:
CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CCC(CC3)(CC4)CCC(=O)O
Current Developer:
CV Therapeutics
1.A1 adenosine receptor antagonists, agonists, and allosteric enhancers.
Kiesman WF1, Elzein E, Zablocki J. Handb Exp Pharmacol. 2009;(193):25-58. doi: 10.1007/978-3-540-89615-9_2.
Intense efforts of many pharmaceutical companies and academicians in the A(1) adenosine receptor (AR) field have led to the discovery of clinical candidates that are antagonists, agonists, and allosteric enhancers. The A(1)AR antagonists currently in clinical development are KW3902, BG9928, and SLV320. All three have high affinity for the human (h) A(1)AR subtype (hA(1) K (i) < 10 nM), > 200-fold selectivity over the hA(2A) subtype, and demonstrate renal protective effects in multiple animal models of disease and pharmacologic effects in human subjects. In the A(1)AR agonist area, clinical candidates have been discovered for the following conditions: atrial arrhythmias (tecadenoson, selodenoson and PJ-875); Type II diabetes and insulin sensitizing agents (GR79236, ARA, RPR-749, and CVT-3619); and angina (BAY 68-4986). The challenges associated with the development of any A(1)AR agonist are to obtain tissue-specific effects but avoid off-target tissue side effects and A(1)AR desensitization leading to tachyphylaxis.
2.Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats.
Gill A1, Wortham K, Costa D, Davis W, Ticho B, Whalley E. Am J Nephrol. 2009;30(6):521-6. doi: 10.1159/000248762. Epub 2009 Oct 13.
BACKGROUND/AIMS: Cisplatin (CIS) induces nephrotoxicity partly through renal vasoconstriction and decreased glomerular filtration effects thought to involve adenosine acting on adenosine A(1) receptors (A1Rs). We studied the effect of the orally active, A1R antagonist tonapofylline (BG9928) on biochemical measures of renal function in CIS-induced acute kidney injury (AKI) in rats.
3.Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects.
Li Z1, TenHoor C, Marbury T, Swan S, Ticho B, Rogge M, Nestorov I. J Clin Pharmacol. 2011 Jul;51(7):1004-14. doi: 10.1177/0091270010377633. Epub 2010 Oct 6.
Tonapofylline is an antagonist of adenosine A1 receptor being developed for heart failure. In the present studies, pharmacokinetic characteristics, including dose proportionality, bioavailability, and effects of gender and food, were evaluated in healthy subjects receiving single-dose tonapofylline (0.2-375 mg) in a parallel or crossover design. Following oral administration, tonapofylline concentrations mostly peaked within 3 hours and declined over time in a multiple phasic manner. Based on a power model, dose proportionality of peak concentration (C(max)), area under the time-concentration curve for all values (AUC(all)), and area under the time-concentration curve to infinity (AUC(inf)) was concluded in a clinical setting. The bioavailability of tonapofylline was 81.2% (90% confidence interval, 70.6%-93.5%). Following intravenous administration, the steady-state volume of distribution of tonapofylline was estimated to be 756 mL/kg. The total clearance of tonapofylline was low (64.
4.Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects.
Li Z1, Tenhoor C, Marbury T, Swan S, Zhu Y, Ticho B. Int J Clin Pharmacol Ther. 2011 Sep;49(9):563-70.
OBJECTIVE: The study was conducted to characterize the pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 142642-31-7 PD 138142

PD 138142
(CAS: 142642-31-7)

PD 138142 is a water soluble Sterol O-acyltransferase inhibitor. Triacylglycerol secretion is decreased in the presence of PD-138142-15. Preclinical development...

CAS 1015474-32-4 CC122

CC122
(CAS: 1015474-32-4)

CC122 is a novel agent for DLBCL. It is an orally available pleiotropic pathway modulator. It has antitumor and immunomodulatory activity. It is used for the tr...

CAS 1802326-66-4 JNJ 63533054

JNJ 63533054
(CAS: 1802326-66-4)

JNJ 63533054 is a potent and selective GPR139 agonist (EC50 = 16 nM) that is brain and cell penetrant. JNJ 63533054 is selective for GPR139 over a panel of GPCR...

CAS 585531-74-4 BFCAs-1

BFCAs-1
(CAS: 585531-74-4)

BFCAs-1 is a polyamino polycarboxylic bifunctional chelating agent, which has a broad range of applications in chemistry, biology and medicine and diagnostic im...

CAS 652-67-5 Isosorbide

Isosorbide
(CAS: 652-67-5)

Isosorbide is a heterocyclic compound that is derived from glucose, used as a diuretic.

CAS 1069046-00-9 ASB14780

ASB14780
(CAS: 1069046-00-9)

ASB14780 is a potent and oral inhibitor of cytosolic phospholipase A2α (cPLA2α; IC50 = 0.020 µM in vitro and 0.54 - 0.64 µM in whole blood assay) with anti-infl...

CAS 110314-48-2 Adolezesin

Adolezesin
(CAS: 110314-48-2)

Adozelesin is an experimental antitumor drug of the duocarmycin class. It is the first of a class of DNA-sequence-selective alkylating agents. It binds to and a...

JNJ 42396302
(CAS: 1298030-18-8)

JNJ 42396302 is an Antipsychotics originated by Janssen-Cilag. But no development has been reported yet.

Chemical Structure

CAS 340021-17-2 Tonapofylline

Quick Inquiry

Verification code

Featured Items